| Cash Flow | 2025-09-30 |
|---|---|
| Net income (loss) | 2,819,021 |
| Depreciation and amortization | 41,522 |
| Loss on extinguishment of debt | -6,329,593 |
| Change in value of contingent consideration | 370,000 |
| Change in value of equity securities | 156,849 |
| Stock-based compensation expense | 181,312 |
| Gain on bankruptcy of subsidiary | 12,019,227 |
| Long-lived asset impairment | 831,915 |
| Gain on settlement of accounts payable | 22,324 |
| Amortization of debt issuance cost | 18,495 |
| Other receivables | 6,407 |
| Prepaid expenses/deposits | -269,264 |
| Accounts payable | 532,206 |
| Accrued expenses | 205,738 |
| Other current liabilities | 0 |
| Operating leases, net | -3,369 |
| Net cash used in operating activities | -1,349,110 |
| Sale of equitable securities | 544,700 |
| Net cash used in investing activities | 544,700 |
| Repayment of finance agreement | 271,643 |
| Proceeds from notes payable | 1,615,000 |
| Net cash provided by financing activities | 1,343,357 |
| Effect of exchange rates on cash | -6,839 |
| Net change in cash | 532,108 |
| Cash and cash equivalents at beginning of period | 92,700 |
| Cash and cash equivalents at end of period | 624,808 |
Lunai Bioworks Inc. (LNAI)
Lunai Bioworks Inc. (LNAI)